FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048937511> ?p ?o ?g. }

• W3048937511 abstract "Abstract Background Pyrotinib was well tolerated but its efficacy was unsatisfactory in patients with HER2‐positive gastric cancer (GC) (NCT02378389). This study was to optimize the efficacy of pyrotinib. Methods Human GC cell lines and AVATAR mice were used to explore the refractory mechanisms of pyrotinib. A pyrotinib‐combined strategy was proposed, which was validated in preclinical AVATAR mouse and in clinical patients enrolled in a phase I clinical trial (NCT03480256). Results Dysregulation of CCND1‐CDK4/6‐Rb axis might be the key to pyrotinib refractory. The strategy of pyrotinib combined with a CDK4/6 inhibitor SHR6390 was proposed and validated in preclinical AVATAR mouse, which was successfully verified in clinical patients. For five patients treated with pyrotinib plus SHR6390 who had available response evaluation, the best response was partial response in three patients, stable disease in one patient, and progressive disease in one patient. The progression‐free survival times were 120, 200, 532, 109, and 57 days, respectively. Conclusions This translational study suggests that pyrotinib combined with SHR6390 may serve as a promising strategy for patients with HER2‐positive GC. Trial registration The ClinicalTrials.gov identifiers are NCT02378389 ( https://clinicaltrials.gov/ct2/show/study/NCT02378389 , registered in 11 February 2015) and NCT03480256 ( https://clinicaltrials.gov/ct2/show/study/NCT03480256 , registered in 8 March 2018)." @default.
• W3048937511 created "2020-08-18" @default.
• W3048937511 creator A5006511913 @default.
• W3048937511 creator A5013718591 @default.
• W3048937511 creator A5046118596 @default.
• W3048937511 creator A5052386864 @default.
• W3048937511 creator A5052883326 @default.
• W3048937511 creator A5053270853 @default.
• W3048937511 creator A5058408659 @default.
• W3048937511 creator A5059392900 @default.
• W3048937511 creator A5061570382 @default.
• W3048937511 creator A5072793694 @default.
• W3048937511 creator A5074640107 @default.
• W3048937511 creator A5075596275 @default.
• W3048937511 creator A5079097113 @default.
• W3048937511 creator A5081643835 @default.
• W3048937511 creator A5084407437 @default.
• W3048937511 date "2020-08-01" @default.
• W3048937511 modified "2023-10-13" @default.
• W3048937511 title "Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients" @default.
• W3048937511 cites W1909506734 @default.
• W3048937511 cites W1914623042 @default.
• W3048937511 cites W1995242599 @default.
• W3048937511 cites W2008322008 @default.
• W3048937511 cites W2017863062 @default.
• W3048937511 cites W2020372547 @default.
• W3048937511 cites W2042174846 @default.
• W3048937511 cites W2059411043 @default.
• W3048937511 cites W2073827381 @default.
• W3048937511 cites W2100439220 @default.
• W3048937511 cites W2159459001 @default.
• W3048937511 cites W2166199281 @default.
• W3048937511 cites W2169560977 @default.
• W3048937511 cites W2185378752 @default.
• W3048937511 cites W2290950904 @default.
• W3048937511 cites W2291007149 @default.
• W3048937511 cites W2299045691 @default.
• W3048937511 cites W2465099763 @default.
• W3048937511 cites W2527881353 @default.
• W3048937511 cites W2551315898 @default.
• W3048937511 cites W2598685895 @default.
• W3048937511 cites W2609953159 @default.
• W3048937511 cites W2613098450 @default.
• W3048937511 cites W2782896696 @default.
• W3048937511 cites W2806564245 @default.
• W3048937511 cites W2889391845 @default.
• W3048937511 cites W2892163061 @default.
• W3048937511 cites W2914556350 @default.
• W3048937511 cites W2990894089 @default.
• W3048937511 cites W3034951790 @default.
• W3048937511 doi "https://doi.org/10.1002/ctm2.148" @default.
• W3048937511 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7424666" @default.
• W3048937511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32898333" @default.
• W3048937511 hasPublicationYear "2020" @default.
• W3048937511 type Work @default.
• W3048937511 sameAs 3048937511 @default.
• W3048937511 citedByCount "16" @default.
• W3048937511 countsByYear W30489375112021 @default.
• W3048937511 countsByYear W30489375112022 @default.
• W3048937511 countsByYear W30489375112023 @default.
• W3048937511 crossrefType "journal-article" @default.
• W3048937511 hasAuthorship W3048937511A5006511913 @default.
• W3048937511 hasAuthorship W3048937511A5013718591 @default.
• W3048937511 hasAuthorship W3048937511A5046118596 @default.
• W3048937511 hasAuthorship W3048937511A5052386864 @default.
• W3048937511 hasAuthorship W3048937511A5052883326 @default.
• W3048937511 hasAuthorship W3048937511A5053270853 @default.
• W3048937511 hasAuthorship W3048937511A5058408659 @default.
• W3048937511 hasAuthorship W3048937511A5059392900 @default.
• W3048937511 hasAuthorship W3048937511A5061570382 @default.
• W3048937511 hasAuthorship W3048937511A5072793694 @default.
• W3048937511 hasAuthorship W3048937511A5074640107 @default.
• W3048937511 hasAuthorship W3048937511A5075596275 @default.
• W3048937511 hasAuthorship W3048937511A5079097113 @default.
• W3048937511 hasAuthorship W3048937511A5081643835 @default.
• W3048937511 hasAuthorship W3048937511A5084407437 @default.
• W3048937511 hasBestOaLocation W30489375111 @default.
• W3048937511 hasConcept C121332964 @default.
• W3048937511 hasConcept C121608353 @default.
• W3048937511 hasConcept C126322002 @default.
• W3048937511 hasConcept C142424586 @default.
• W3048937511 hasConcept C143998085 @default.
• W3048937511 hasConcept C2780668389 @default.
• W3048937511 hasConcept C535046627 @default.
• W3048937511 hasConcept C71924100 @default.
• W3048937511 hasConcept C87355193 @default.
• W3048937511 hasConceptScore W3048937511C121332964 @default.
• W3048937511 hasConceptScore W3048937511C121608353 @default.
• W3048937511 hasConceptScore W3048937511C126322002 @default.
• W3048937511 hasConceptScore W3048937511C142424586 @default.
• W3048937511 hasConceptScore W3048937511C143998085 @default.
• W3048937511 hasConceptScore W3048937511C2780668389 @default.
• W3048937511 hasConceptScore W3048937511C535046627 @default.
• W3048937511 hasConceptScore W3048937511C71924100 @default.
• W3048937511 hasConceptScore W3048937511C87355193 @default.
• W3048937511 hasFunder F4320335777 @default.
• W3048937511 hasIssue "4" @default.
• W3048937511 hasLocation W30489375111 @default.
• W3048937511 hasLocation W30489375112 @default.
• W3048937511 hasLocation W30489375113 @default.

• next